Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 406 results for "mirati"

Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Nasdaq

Mirati Therapeutics closes public offering of 2.59m common sha...

Oncology company Mirati Therapeutics This public offering includes the exercise in full by the underwriters of their option to purchase up to 337,500 additional shares of common stock. Before deducting underwriting discounts and commissions and ... BusinessWeek, 3 weeks ago
[x]  

4 images for mirati

InsiderMonkey.com, 3 weeks ago
Nasdaq, 4 weeks ago
KXXV-TV, 4 weeks ago
Pharmaceutical Business Review, 1 month ago

Mirati Therapeutics, Inc. (0001576263) (Subject)

 SEC Filings3 weeks ago SC 13D/A - Mirati Therapeutics, Inc. (0001576263) (Subject)  SEC4 weeks ago SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)  SEC1 month ago 424B5 - Mirati Therapeutics, Inc. (0001576263) (Filer)  SEC1 month ago
InsiderMonkey.com

Mirati Therapeutics Inc (MRTX) is Trading Lower on Unusual Volume for February 27

Mirati Therapeutics Inc ($MRTX) experienced unusually high volume on Feb. 27, as the stock lost 0.83% to a closing price of $23.77. The stock saw 148,548 shares trade hands over the course of the day on 783 trades. Given that the stock's average ...
 Equities.com4 days ago Insider Selling: Mirati Therapeutics SVP Jamie Christensen Sells 4,750 Shares of Stock (MRTX)  Mideast Time1 week ago Mirati Therapeutics Inc. (MRTX): Baker Bros. Advisors Increases Stake in Growing Stock  InsiderMonkey.com3 weeks ago Insider Buying: Bros. Advisors Lp Baker Buys 425,000 Shares of Mirati Therapeutics Stock (MRTX)  Ticker Report3 weeks ago
[x]  

Mirati Therapeutics raises $51.75 million in public offering of common stock

(MarketLine Financial Deals Tracker via COMTEX) -- Mirati Therapeutics, Inc., a US-based biopharmaceutical company that develops and commercializes therapeutics for the treatment of patients with cancer, has completed its public offering of ...
 TradingCharts.com3 weeks ago

Analysts Give $28.60 Consensus Target Price to Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ:MRTX) has received an average broker rating score of 1.00 (Strong Buy) from the six analysts that provide coverage for the stock, Zacks Investment Research reports. Six equities research analysts have rated the stock with ...
 WKRB News2 weeks ago Analysts Give $30.40 Consensus Price Target to Mirati Therapeutics (NASDAQ:MRTX)  Ticker Report1 month ago Brokerages Anticipate Mirati Therapeutics to Post ($1.00) EPS (NASDAQ:MRTX)  Mideast Time1 month ago

MIRATI THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)

 4 Traders1 month ago ASSEMBLY BIOSCIENCES : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)  4 Traders2 weeks ago

West Coast Biotech Roundup: Tracon, Mirati, Third Rock, & Dendreon

This week, well take our roundup on a West Coast roadtrip from south to north. First, down San Diego way, the news the past seven days was mostly financial, led by Tracon Pharmceuticals IPO. In San Francisco, Genentech had breakthrough news, while ...
 Xconomy3 weeks ago
Pharmaceutical Business Review

Mirati starts dosing in Phase II trial of mocetinostat to treat non-Hodgkin's lymphoma

US-based oncology firm Mirati Therapeutics has started dosing patients in an investigator-sponsored Phase II clinical trial of mocetinostat to treat relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The ...
 Pharmaceutical Business Review1 month ago MIRATI THERAPEUTICS : begins dosing in Phase II trial of mocetinostat to treat bladder cancer  4 Traders1 month ago Mirati begins dosing in Phase II trial of mocetinostat to treat bladder cancer  Pharmaceutical Business Review1 month ago Mirati Therapeutics : starts dosing in Phase II trial of mocetinostat to treat non-Hodgkin's lymphoma  4 Traders1 month ago

Mirati Therapeutics Price Target Raised to $37.00

Filed Under: Analysts Price Targets • Market News Research analysts at Piper Jaffray raised their price target on shares of Mirati Therapeutics (NASDAQ:MRTX) from $31.00 to $37.00 in a report released on Monday. The firm currently has an ...
 American Banking News2 months ago

Leiomyosarcoma Therapeutics Pipeline Review, H1 2015 - Analysis of 6 Companies & 10 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/8sczn5/leiomyosarcoma) has announced the addition of the "Leiomyosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the ...
 Individual.com1 week ago Research and Markets: Leiomyosarcoma Therapeutics Pipeline Review, H1 2015 - Analysis of 6 Companies & 10 Drug...  TeleTrader.com1 week ago Leiomyosarcoma Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report at RnRMarketResearch.com  Digital Journal4 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - mirati
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less